Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study.
暂无分享,去创建一个
C. Samama | P. Coriat | O. Langeron | X. Capdevila | J. Bernière | N. Rosencher | M. Pégoix | Patricia Rouche
[1] D. Raines,et al. Aprotinin administration and pulmonary thromboembolism during orthotopic liver transplantation: report of two cases. , 2001, Anesthesia and analgesia.
[2] C. Colwell,et al. Prevention of venous thromboembolism. , 1994, Chest.
[3] C. Samama,et al. Structure, Pharmacology, and Clinical Use of Antifibrinolytic Agents , 2001 .
[4] R. Hall,et al. Aprotinin Decreases Exposure to Allogeneic Blood During Primary Unilateral Total Hip Replacement* , 2000, The Journal of bone and joint surgery. American volume.
[5] L. Lindgren,et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study , 2000, The Lancet.
[6] J. Rütt,et al. A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. , 1998, European journal of anaesthesiology.
[7] B. Chaitman,et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. , 1998, The Journal of thoracic and cardiovascular surgery.
[8] W. Dietrich,et al. Incidence of hypersensitivity reactions. , 1998, The Annals of thoracic surgery.
[9] X. Capdevila,et al. Aprotinin Decreases Blood Loss and Homologous Transfusions in Patients Undergoing Major Orthopedic Surgery , 1998, Anesthesiology.
[10] M. McCarroll,et al. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. , 1996, Journal of clinical anesthesia.
[11] F. Mercuriali,et al. Proposal of an algorithm to help the choice of the best transfusion strategy. , 1996, Current medical research and opinion.
[12] M. Abel,et al. Fatal anaphylactic shock after aprotinin reexposure in cardiac surgery. , 1995, Anesthesia and analgesia.
[13] R. Bourne,et al. Aprotinin Decreases Blood Loss in Patients Undergoing Revision or Bilateral Total Hip Arthroplasty , 1995, Anesthesia and analgesia.
[14] C. Samama,et al. Aprotinin to decrease bleeding and intraoperative blood transfusion requirements during descending thoracic and thoracoabdominal aortic aneurysmectomy using cardiopulmonary bypass , 1994, Annals of vascular surgery.
[15] J. Levy,et al. Pharmacokinetics of Aprotinin in Preoperative Cardiac Surgical Patients , 1994, Anesthesiology.
[16] M. Lamy,et al. High‐dose Aprotinin Reduces Blood Loss in Patients Undergoing Total Hip Replacement Surgery , 1994, Anesthesiology.
[17] J. Haberer,et al. Anaphylactic reaction to aprotinin during cardiac surgery , 1993, Anaesthesia.
[18] T. Feeley,et al. Use of aprotinin to reduce intraoperative bleeding. , 1993, The Western journal of medicine.
[19] S. Bélisle,et al. Low-dose aprotinin infusion is not clinically useful to reduce bleeding and transfusion of homologous blood products in high-risk cardiac surgical patients , 1993, Canadian journal of anaesthesia = Journal canadien d'anesthesie.
[20] F. Loop,et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. , 1992, The Annals of thoracic surgery.
[21] J. Griffin,et al. Aprotinin (trasylol) is a competitive inhibitor of activated protein C. , 1989, Thrombosis research.
[22] K. M. Taylor,et al. EFFECT OF APROTININ ON NEED FOR BLOOD TRANSFUSION AFTER REPEAT OPEN-HEART SURGERY , 1987, The Lancet.